The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems
Abstract
Metastable thermodynamic states are frequently encountered in pharmaceutical systems, in the intentional or unintentional creation of supersaturation, in the crystallization of desired solid-state modifications, and in the control of solid-phase conversions during isolation, manufacturing, storage, and dissolution.1-4 Some examples in which metastable states are encountered include solid solutions, freeze-concentrated solutions, solutions of weak acids or bases exposed to a pH change, solutions prepared by dissolving a solid-state modification with a higher solubility (higher free energy), and residual solutions during filtration, granulation, and drying. Because crystallization provides a way of reducing the free energy of metastable thermodynamic states, the extent to which metastable states can be maintained is determined by the crystallization mechanisms and kinetics.5-16 What is surprising, however, is that despite the important role that crystallization has in process control and in determining solid-phase outcomes, crystallization phenomena are often neglected in the pharmaceutical industry until a problem is encountered. While emphasis is often given to the knowledge of equilibrium phase diagrams with the purpose of identifying the concentration and temperature regions of thermodynamic stability of solid phases, information on crystallization processes can only be obtained by combining studies of thermodynamic properties with kinetic measurements. Cases of unwanted or previously unknown nucleation events abound. Dunitz and Bernstein17 documented cases of “disappearing or elusive polymorphs” that provide evidence for the consequences of poor process control in crystallization of polymorphic systems. The recent shortage in the supply of capsules of the HIV protease inhibitor Norvir (indinavir), due to the sudden formation of a crystalline structure different from the one harvested for months,18 illustrates the decisive role that nucleation mechanisms and kinetics have on crystallization. Nichols and Frampton19 have reported considerable efforts that failed to crystallize the metastable polymorph of paracetamol as described in the initial publication of the crystal structure.20 The critical role of crystallization kinetics in determining the appearance of crystalline modifications is also recognized by the FDA and described in the guidelines for the manufacture of drug substances:21 “Appropriate manufacturing and control procedures (including in-process testing when needed) should be established for the production of the desired solid-state form(s). It should be emphasized that the manufacturing process (or storage condition) is responsible for producing particular polymorphs or solvates; the control methods merely determine the outcome.” Even when the parameters that regulate crystallization phenomena are neglected, the illusion of process control is motivated by a crystallization process that yields the desired productssolid phase modification, shape, or size distributionsand by the robust analytical methods used for solid state characterization. This situation is greatly complicated by the recent emphasis on an exclusively * Corresponding author. Tel: 734-763-0101. Fax: 734-763-2022. e-mail: nrh@umich.edu. † University of Michigan. ‡ Dupont Pharmaceuticals. July 1999
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The growth of crystals and the equilibrium structure of their surfaces
Burton, W. K., Cabrera, N., & Frank, F. C. (1951) · Philosophical Transactions of the Royal Society of London. Series A, Mathematical and Physical Sciences · doi:10.1098/rsta.1951.0006 · Cited by 5,339
Supramolecular Synthons in Crystal Engineering—A New Organic Synthesis
Desiraju, G. R. (1995) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199523111 · Cited by 4,856
Kinetische Behandlung der Keimbildung in übersättigten Dämpfen
Becker, R., & Döring, W. (1935) · Annalen der Physik · doi:10.1002/andp.19354160806 · Cited by 3,155
Under what conditions can a glass be formed?
Turnbull, D. (1969) · Contemporary Physics · doi:10.1080/00107516908204405 · Cited by 2,229
Rate of Nucleation in Condensed Systems
Turnbull, D., & Fisher, J. C. (1949) · The Journal of Chemical Physics · doi:10.1063/1.1747055 · Cited by 2,159
Studien über die Bildung und Umwandlung fester Körper: 1. Abhandlung: Übersättigung und Überkaltung
Ostwald, W. (1897) · Zeitschrift für Physikalische Chemie · doi:10.1515/zpch-1897-2233 · Cited by 2,103
Handbook of Industrial Crystallization
(2002) · Elsevier eBooks · doi:10.1016/b978-0-7506-7012-8.x5000-9 · Cited by 1,316
Modern Crystallography III: Crystal Growth
Chernov, A. A. (1984) · Springer Series in Solid-State Sciences · doi:10.1007/978-3-642-81835-6 · Cited by 1,101
Crystallization Technology Handbook
(2001) · CRC Press eBooks · doi:10.1201/9780203908280 · Cited by 922
Are Crystal Structures Predictable?
Gavezzotti, A. (1994) · Accounts of Chemical Research · doi:10.1021/ar00046a004 · Cited by 921
Cited by
From Molecules to Crystal Engineering: Supramolecular Isomerism and Polymorphism in Network Solids
Moulton, B., & Zaworotko, M. J. (2001) · Chemical Reviews · doi:10.1021/cr9900432 · Cited by 6,395
Cyclodextrins as pharmaceutical solubilizers
Brewster, M. E., & Loftsson, T. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.012 · Cited by 1,882
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Supersaturating Drug Delivery Systems: The Answer to Solubility-Limited Oral Bioavailability?
Brouwers, J., Brewster, M. E., & Augustijns, P. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21650 · Cited by 947
Vippagunta, S. R., Brittain, H. G., & Grant, D. J. W. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00097-7 · Cited by 670
Metadata
- Authors
- Rodríguez‐hornedo, N., & Murphy, D.
- Venue
- Journal of Pharmaceutical Sciences
- Publisher
- American Geophysical Union (AGU)
- Published
- 1999-07
- Volume
- 88
- Issue
- 7
- Pages
- 651-660
- ISSN
- 0022-3549 (ISSN-L)
- OpenAlex
- W2070989998
- Cited by
- 371
- References
- 51
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. https://app.cochat.ai/papers/10.1021/js980490h
- The paper
- Rodríguez‐hornedo, N., & Murphy, D. (1999). Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. Journal of Pharmaceutical Sciences. https://doi.org/10.1021/js980490h
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.